Insider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 4,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $140.78, for a total transaction of $563,120.00. Following the completion of the transaction, the director now owns 9,704 shares of the company’s stock, valued at $1,366,129.12. This trade represents a 29.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Gail Boxer Marcus also recently made the following trade(s):

• On Wednesday, March 12th, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00.

Natera Stock Down 3.5 %

NTRA stock opened at $133.87 on Friday. The business’s 50 day simple moving average is $156.81 and its 200 day simple moving average is $151.40. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00. The firm has a market capitalization of $18.10 billion, a PE ratio of -76.06 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NTRA. The Manufacturers Life Insurance Company increased its stake in shares of Natera by 87.3% during the third quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock worth $8,621,000 after purchasing an additional 31,649 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Natera by 5.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,339 shares of the medical research company’s stock valued at $3,344,000 after buying an additional 1,263 shares in the last quarter. Captrust Financial Advisors increased its position in Natera by 108.7% during the 3rd quarter. Captrust Financial Advisors now owns 5,689 shares of the medical research company’s stock worth $722,000 after buying an additional 2,963 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Natera during the third quarter worth $238,000. Finally, Benjamin Edwards Inc. boosted its position in shares of Natera by 15,167.3% in the third quarter. Benjamin Edwards Inc. now owns 7,481 shares of the medical research company’s stock valued at $950,000 after acquiring an additional 7,432 shares during the period. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NTRA shares. Canaccord Genuity Group reissued a “buy” rating and issued a $180.00 price target on shares of Natera in a research note on Wednesday, February 26th. Guggenheim lifted their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Piper Sandler upped their price target on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. The Goldman Sachs Group lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, Robert W. Baird boosted their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.